Jöerg Wischhusen

480 total citations
9 papers, 89 citations indexed

About

Jöerg Wischhusen is a scholar working on Oncology, Molecular Biology and Rheumatology. According to data from OpenAlex, Jöerg Wischhusen has authored 9 papers receiving a total of 89 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Rheumatology. Recurrent topics in Jöerg Wischhusen's work include GDF15 and Related Biomarkers (3 papers), RNA modifications and cancer (2 papers) and Cancer Cells and Metastasis (2 papers). Jöerg Wischhusen is often cited by papers focused on GDF15 and Related Biomarkers (3 papers), RNA modifications and cancer (2 papers) and Cancer Cells and Metastasis (2 papers). Jöerg Wischhusen collaborates with scholars based in Germany, Switzerland and Austria. Jöerg Wischhusen's co-authors include Martin Heisig, C. Hotz, Werner Goebel, Ulf R. Rapp, Antoine Galmiche, Joachim Fensterle, Ivaylo Gentschev, Birgit Bergmann, Eckart Meese and Christina Backes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jöerg Wischhusen

9 papers receiving 89 citations

Peers

Jöerg Wischhusen

MB

IMMUN

CR

ONCOL

BE

Daoud Sheban Israel

Arman Öner Germany

Waleed M. Kholosy Netherlands

Ruth Brignall United Kingdom

Sean-Luc Shanahan United States

Alessio Bevilacqua Switzerland

M. Teresa Ciudad Canada

Selena Kazancioglu Türkiye

Adam Akkad United States

Stacey Price United Kingdom

Daoud Sheban Israel

Jöerg Wischhusen

105 ×2.2

MB

14 ×0.4

IMMUN

26 ×1.2

CR

31 ×1.6

ONCOL

6 ×0.5

BE

Citations per year, relative to Jöerg Wischhusen Jöerg Wischhusen (= 1×) peers Daoud Sheban

Countries citing papers authored by Jöerg Wischhusen

Since Specialization

Citations

This map shows the geographic impact of Jöerg Wischhusen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jöerg Wischhusen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jöerg Wischhusen more than expected).

Fields of papers citing papers by Jöerg Wischhusen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jöerg Wischhusen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jöerg Wischhusen. The network helps show where Jöerg Wischhusen may publish in the future.

Co-authorship network of co-authors of Jöerg Wischhusen

This figure shows the co-authorship network connecting the top 25 collaborators of Jöerg Wischhusen. A scholar is included among the top collaborators of Jöerg Wischhusen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jöerg Wischhusen. Jöerg Wischhusen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Haake, Markus, Matthias Kist, Sabrina Genßler, et al.. (2023). 1049 SHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T-cells. SHILAP Revista de lepidopterología. A1156–A1156. 1 indexed citations

2.

Wischhusen, Jöerg, Markus Haake, Sabrina Genßler, et al.. (2021). Tumor-derived GDF-15 to suppress t-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.. Journal of Clinical Oncology. 39(15_suppl). e14532–e14532. 2 indexed citations

3.

Melero, Ignacio, Emiliano Calvo, Reinhard Dummer, et al.. (2021). A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).. Journal of Clinical Oncology. 39(15_suppl). TPS2658–TPS2658. 5 indexed citations

4.

Stüber, Tanja, et al.. (2018). Effect of immunotherapy of triple negative breast cancer with ROR1 CAR T cells in combination with the TGF-ß receptor I kinase inhibitor SD-208.. Journal of Clinical Oncology. 36(15_suppl). e15050–e15050. 2 indexed citations

5.

Kumar, Praveen, Ulrike Naumann, Ludwig Aigner, et al.. (2015). Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53.. PubMed. 5(11). 3436–45. 8 indexed citations

6.

Keller, Andreas, Petra Leidinger, Christina Backes, et al.. (2012). Whole miRNome-Wide Differential Co-Expression of MicroRNAs. Genomics Proteomics & Bioinformatics. 10(5). 285–294. 18 indexed citations

7.

Heisig, Martin, C. Hotz, Jöerg Wischhusen, et al.. (2010). Shigella Mediated Depletion of Macrophages in a Murine Breast Cancer Model Is Associated with Tumor Regression. PLoS ONE. 5(3). e9572–e9572. 43 indexed citations

8.

Menaa, Farid, et al.. (2009). Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?. PubMed. 144(3). 287–96. 9 indexed citations

9.

Engel, J., et al.. (2007). The role of regulatory T cells in ovarian cancer. International Journal of Gynecological Cancer. 17(4). 764–770. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact